SABRINA BOLIANITES: Open Payments
NPI 1043790413 · CONCORD, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$912 in 14 payments from 10 companies in 2025. Trend: 2023 $608 · 2024 $911 · 2025 $912
Food & beverage: $912
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $156 |
| Blueprint Medicines Corporation | 2 | $145 |
| SERVIER PHARMACEUTICALS LLC | 1 | $124 |
| Gilead Sciences, Inc. | 1 | $109 |
| Amgen Inc. | 1 | $100 |
| E.R. Squibb & Sons, L.L.C. | 1 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Novartis Pharmaceuticals Corporation | 1 | $64 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| Genentech USA, Inc. | 1 | $19 |
Products named: Trodelvy, IMDELLTRA (AMG757), Enhertu, REBLOZYL, NINLARO, SCEMBLIX, DATROWAY, TAGRISSO.
Industry payments across NH — which companies pay providers there.
